Last €21.24 EUR
Change Today +0.195 / 0.93%
Volume 0.0
ILR On Other Exchanges
As of 1:46 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

impax laboratories inc (ILR) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/4/14 - €22.90
52 Week Low
10/16/13 - €14.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMPAX LABORATORIES INC (ILR)

impax laboratories inc (ILR) Related Businessweek News

No Related Businessweek News Found

impax laboratories inc (ILR) Details

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The Global Pharmaceuticals Division develops, manufactures, sells, and distributes generic pharmaceutical products through its global products sales channel for sales of generic prescription products directly to wholesalers, retail drug chains, and others; private label product sales channel for generic over-the-counter (OTC) and prescription products to unrelated third-party customers; Rx partner sales channel for generic prescription products through unrelated third-party pharmaceutical entities; and OTC partner sales channel for OTC products through unrelated third-party pharmaceutical entities, as well as offers research and development services. The Impax Pharmaceutical Division develops proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson’s disease, and postherpetic neuralgia, as well as promotes third-party branded pharmaceutical products through its specialty sales force. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop and manufacture controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.

973 Employees
Last Reported Date: 02/25/14
Founded in 1993

impax laboratories inc (ILR) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $385.0K
President of Impax Pharmaceuticals Division
Total Annual Compensation: $500.5K
President of Global Pharmaceuticals Division
Total Annual Compensation: $486.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $470.2K
Compensation as of Fiscal Year 2013.

impax laboratories inc (ILR) Key Developments

Impax Laboratories Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-12-2014 08:40 AM

Impax Laboratories Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-12-2014 08:40 AM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States. Speakers: Bryan M. Reasons, Chief Financial Officer, Principal Accounting Officer and Senior Vice President of Finance, George Frederick Wilkinson, Chief Executive Officer and President.

Impax Laboratories Inc. Amends and Restates its Bylaws

On and effective May 14, 2014, the Board of directors of Impax Laboratories Inc. amended and restated its bylaws. The Amended and Restated Bylaws amend Article III, Section 14 of the Bylaws to increase the maximum number of directors authorized to serve on the Board from eight to nine. As amended, this section provides that the authorized number of directors shall be no less than one nor more than nine.

Impax Laboratories Inc. Reports Un-Audited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Year 2014

Impax Laboratories Inc. reported un-audited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported adjusted net income of $16.5 million, or $0.24 per diluted share compared to of $25.3 million, or $0.37 per diluted share in the prior year period. On a GAAP basis, the company recorded net income of $6.4 million, or $0.09 per diluted share compared to net income of $105.4 million, or $1.55 per diluted share in the prior year period. GAAP net income and GAAP earnings per diluted share declined in the first quarter 2014 primarily due to the recognition of one-time pre-tax payments in the first quarter 2013 totaling $150.0 million in connection with previously announced settlement and license agreements. Total revenues for the first quarter 2014 were $118.7 million, compared to $148.5 million in the prior year period. The company reported income from operations of $8.2 million compared to $4.3 million, income before income taxes of $8.6 million compared to $153.7 million and adjusted EBITDA of $34.8 million compared to $43.3 million for the last year. The company provided earnings guidance for the year 2014. For the year, the company expects adjusted gross margins as a percent of total revenue are expected to be in the mid 50% range, capital expenditures of approximately $40.0 million to $45.0 million and effective tax rate of approximately 32% to 34% on a GAAP basis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILR:GR €21.24 EUR +0.195

ILR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ILR.
View Industry Companies

Industry Analysis


Industry Average

Valuation ILR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPAX LABORATORIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at